Axsome Therapeutics (AXSM)
(Real Time Quote from BATS)
$66.48 USD
+0.76 (1.16%)
Updated Apr 19, 2024 09:37 AM ET
3-Hold of 5 3
F Value C Growth D Momentum F VGM
Axsome Therapeutics (AXSM) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$123.33 | $190.00 | $90.00 | 87.66% |
Price Target
Based on short-term price targets offered by 15 analysts, the average price target for Axsome Therapeutics comes to $123.33. The forecasts range from a low of $90.00 to a high of $190.00. The average price target represents an increase of 87.66% from the last closing price of $65.72.
Analyst Price Targets (15)
Broker Rating
Axsome Therapeutics currently has an average brokerage recommendation (ABR) of 1.31 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 16 brokerage firms. The current ABR compares to an ABR of 1.31 a month ago based on 16 recommendations.
Of the 16 recommendations deriving the current ABR, 13 are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 81.25% and 6.25% of all recommendations. A month ago, Strong Buy made up 81.25%, while Buy represented 6.25%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 13 | 13 | 13 | 12 | 11 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 2 | 2 | 2 | 2 | 2 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.31 | 1.31 | 1.31 | 1.33 | 1.36 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
4/10/2024 | Cantor Fitzgerald & Co | Charles C Duncan | Strong Buy | Strong Buy |
3/28/2024 | Mizuho SecuritiesUSA | Graig Suvannavejh | Strong Buy | Strong Buy |
3/26/2024 | Truist Securities | Joon Lee | Strong Buy | Strong Buy |
3/19/2024 | Robert W. Baird & Co. | Joel L Beatty | Not Available | Strong Buy |
3/4/2024 | H.C. Wainwright & Co. | Raghuram Selvaraju | Strong Buy | Strong Buy |
2/21/2024 | Guggenheim Securities | Yatin Suneja | Strong Buy | Strong Buy |
1/16/2024 | Piper Sandler | David Amsellem | Strong Buy | Strong Buy |
11/7/2023 | SVB Securities | Marc Goodman | Strong Buy | Strong Buy |
10/18/2023 | William Blair | Myles R Minter | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.31 |
ABR (Last week) | 1.31 |
# of Recs in ABR | 16 |
Average Target Price | $123.33 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 84 of 252 |
Current Quarter EPS Est: | -1.21 |